title: Heart transplantation: current status.
abstract: Two hundred ninety-three patients transplanted between March 1979 and October 1990 are reviewed. A comparison of survival curves suggests that our current triple therapy results in a half-life (15 years) which is twice that anticipated with either conventional or CsA and P therapy. Rejection occurs primarily in the first 1-3 months after transplantation and with our current therapy, is rarely seen thereafter. Infection, however, continues to be a threat with an incidence of approximately 10% per year. The major threats to long-term survival appear to be graft arteriosclerosis, infection, and malignancy.
authors.affiliation: Department of Surgery, University of Arizona Health Sciences Center, Tucson.
authors.forename: J G
authors.initials: JG
authors.lastname: Copeland
authors.forename: L J
authors.initials: LJ
authors.lastname: Rosado
authors.forename: G
authors.initials: G
authors.lastname: Sethi
authors.forename: C
authors.initials: C
authors.lastname: Huston
mesh_terms: D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D007166:Immunosuppressive Agents